Head: Dr. rer. nat. André Haase
Our research group focuses on the tumor biology of retinoblastoma (RB) and colorectal carcinoma (CRC). Our overarching goal is to elucidate the molecular mechanisms underlying tumor progression, to identify novel therapeutic targets, and to develop innovative treatment strategies that ultimately contribute to improved patient care. To this end, our group integrates state-of-the-art cell and molecular biology with innovative tumor model systems, functional imaging, and pharmacological development.
Two tumor entities – a complementary research strategy
Retinoblastoma is a rare pediatric ocular tumor characterized by an exceptionally homogeneous genetic background. This unique feature makes retinoblastoma an ideal model system for studying fundamental mechanisms of tumor initiation, metabolic reprogramming, and therapy resistance under clearly defined genetic conditions.
In contrast, colorectal carcinoma represents one of the most genetically heterogeneous malignancies and is among the most common cancers worldwide. The extensive molecular diversity of CRC closely reflects the clinical reality of personalized oncology and enables the evaluation of novel therapeutic approaches under highly variable and clinically relevant conditions.
The parallel investigation of both tumor entities allows us to transfer fundamental oncogenic principles identified in a genetically well-defined model system (RB) to a highly complex clinical scenario (CRC). This strategy enables the identification of robust, tumor-spanning mechanisms while simultaneously facilitating the development of individualized therapeutic approaches.
Our research projects:
A special focus is placed on the functional validation of newly identified targets and the preclinical evaluation of novel therapeutic agents.
Tumor model system: The chorioallantoic membrane of the chicken embryo
The chorioallantoic membrane (CAM) is a thin, highly vascularized membrane surrounding the chicken embryo and physiologically functions as a respiratory organ. It mediates embryonic gas exchange and is therefore characterized by intense perfusion and high metabolic activity.
This unique biological structure makes the CAM an ideal in-ovo tumor model system. Human tumor cells or tumor tissue can be directly applied onto the membrane, where they engraft, become vascularized, and form solid tumors within a few days.
The CAM model enables the investigation of tumor growth, neovascularization (angiogenesis), invasion, and metastasis in a living organism. At the same time, it provides a powerful platform for the preclinical testing of novel drugs and therapeutic strategies under physiologically relevant conditions.
Due to its short experimental duration, high reproducibility, and application prior to the pain-sensitive developmental stage of the embryo, the CAM model fulfills the ethical requirements of the 3R principles to a remarkable extent and serves as a bridge between classical cell culture models and established animal models.
A particular strength of our CAM platform lies in the functional live and real-time imaging of tumor vascularization. We employ advanced laser speckle imaging systems, which allow non-invasive, high-resolution, real-time measurements of blood flow within the CAM. This enables the quantitative assessment of dynamic changes in perfusion, vascular remodeling, and both acute and chronic therapeutic effects.
Using the CAM model, we are able to:
By doing so, we bridge the gap between conventional cell culture models and labor-intensive animal models, establishing a powerful platform for translational cancer research.
Our group combines cutting-edge cell and molecular biology with innovative tumor models, functional imaging, and pharmacological development. Through the close integration of basic research and preclinical validation, we provide a strong foundation for future personalized therapeutic strategies in oncology.
The CAM platform is available for scientific collaborations in the fields of tumor angiogenesis, vascular function, drug testing, and translational oncology. For further information, please contact the group leader, Dr. André Haase.
Copyright © pharmacology 2026
Last update: Feb 09, 2026
